Combining the two classes lowered heart failure admissions but not MACE or major kidney events.
Combined SGLT2 inhibitor plus GLP-1 RA therapy is widely recommended, but randomized evidence that it beats either class alone is thin. In a network meta-analysis of 12 RCTs (99,683 participants), combination therapy did not significantly reduce MACE versus SGLT2i (RR 0.86, 95% CI 0.74-1.01) or GLP-1 RA (RR 0.95, 0.81-1.12), or major adverse kidney events versus SGLT2i (RR 1.05, 0.74-1.49) or GLP-1 RA (RR 0.86, 0.60-1.21). Heart failure admissions were lower than with SGLT2i (RR 0.72, 0.52-0.99) or GLP-1 RA (RR 0.62, 0.45-0.86). All estimates were very low certainty and indirect, since no trial randomized patients to combination versus monotherapy. Combination therapy is reasonable when each drug has its own indication, but expect heart failure benefit rather than proven extra MACE or kidney protection.
The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.